### **Overview** Shaily Engineering Plastics Limited (SEPL) is India’s largest exporter of engineering plastic components and a leading global provider of end-to-end plastic product solutions. Established in 1987 by Mike Sanghvi and currently led by Managing Director Amit Sanghvi, the company has evolved from a two-machine startup into a diversified, precision manufacturing powerhouse with a significant international footprint. Headquartered near Vadodara, Gujarat, SEPL operates **seven advanced manufacturing facilities** — six focused on plastic components and one dedicated to carbon steel furniture — housing **over 200 injection molding machines** (35–1,000 tons). The company employs **more than 2,000 people** and serves a blue-chip global client base across over 40 countries. SEPL combines deep expertise in **advanced polymer processing**, **precision engineering**, **tooling mastery**, and **regulatory compliance** to deliver high-performance, customized, and defect-free solutions for regulated and high-value sectors. --- ### **Core Business Segments** The company is strategically organized into three key verticals: 1. **Healthcare** 2. **Consumer** 3. **Industrial (including Automotive & Appliances)** This restructuring enables focused development, shared process efficiencies, and enhanced competitiveness across high-growth, technology-intensive domains. --- ## **Strategic Highlights (Nov 2025)** ### 1. **Healthcare – The Growth Engine** The healthcare segment has emerged as SEPL’s primary growth driver, transforming the company’s revenue and profitability profile. - **Revenue Contribution:** ~21% in FY25, projected to grow to **25–30% by FY27–28** and potentially **50% within three years**. - **Growth Rate:** 53% YoY in FY25, significantly outpacing overall corporate growth (22%). - **EBITDA Impact:** Higher-than-average margins are lifting corporate returns and RoCE. #### Key Focus Areas: - **GLP-1 Therapies:** Strategic positioning around blockbuster drugs like **Semaglutide** and **Tirzepatide**, with commercial supply scheduled from **FY2026**. - **IP-Led Devices:** 7 proprietary, patent-protected drug delivery platforms developed through **Shaily Innovations Limited (UK subsidiary)**, including: - **ShailyPen Axiom** (HGH, FSH, GLP-1, PTH) - **ShailyPen Maxim** (0–80 IU insulin/GLP-1, reusable/disposable) - **Protean** (insulin pen) - **Neo** (spring-driven pen) - **Toby** (2-step auto-injector) - **Mira:** Wearable injector under development for oncology and high-viscosity biologics. - **Next-Gen Devices:** Focused on usability improvements—e.g., pull-to-activate, push-to-deliver mechanism with built-in dose counter—to enhance patient adherence. #### Contracts & Market Position: - In FY24–25, secured **8 new contracts** with global pharma firms for GLP-1, insulin, PTH, and migraine devices; **6 more in Q3 FY25**. - Selected as **sole supplier** in most GLP-1 engagements. - Over **75% of 55–60 GLP-1 molecules in development** are injectable, reinforcing long-term demand. #### Capacity Expansion: - **₹150 crore capex** allocated to pharma segment; **total FY25 capex: ₹185 crore**. - Plans to scale **pen injector capacity from ~35 million to 80–90 million units annually** by Q1 FY26–27. - Two new production lines under commission (20–25 million units each), one by **Q3 FY26**, the other by **Q1 FY27**. - Expansion based on **customer commitments** and **de-risked financing** via internal accruals and credit lines (no long-term debt). #### Competitive Moats: - Micron-level precision manufacturing - Regulatory certifications: **ISO 13485:2016, ISO 15378:2015, MDSAP, FDA 21 CFR 820** - Global quality compliance and zero-defect culture - Proprietary IP and co-development partnerships - Client trust in confidentiality and performance --- ### 2. **Consumer Segment – Scale and Stability** The consumer vertical remains the **largest revenue contributor (~71% in FY25)**, providing scale and stability while the company transitions toward higher-margin segments. - **Revenue:** ₹561 crores in FY25, up **17% YoY**. - **Customers:** Gillette, P&G, Unilever, and a major **Swedish home furnishings brand**. - **Products:** Home furnishings, FMCG packaging, LED lighting, personal care products, carbon steel furniture. #### Innovations & Capabilities: - Advanced surface treatments: **PVD coating**, **vacuum metallizing**, **hot stamping**, **rotary pad printing**, **ultrasonic welding**, **laser marking**. - Full design-to-delivery support with **integrated LED manufacturing** (SMT assembly, molding, testing). - Emphasis on **sustainability**—recyclable materials, eco-friendly processes aligned with global FMCG trends. #### Growth & Expansion: - Added **2 plastic + 3 steel products** for home furnishing client in Q4 FY25. - Secured **new contracts** with **2 global retail chains**; supply starts Q1 FY26. - Diversifying away from China-led supply chains for clients like the Swedish home furnishings major, which is expanding its **online retail and Indian market presence**. - Consumer revenue expected to grow at **8–10% CAGR** over next 3–5 years. --- ### 3. **Industrial & Automotive – Beneficiary of Supply Chain Shift** The industrial segment grew **12% YoY in FY25** to ₹61 crores and contributes ~8% of total revenue. It benefits from **global decoupling from China** and the **shift toward lightweight, high-performance plastics**. - **Key Applications:** Automotive components, turbochargers, appliance parts, electrical systems. - **Technology:** **Metal-to-plastic conversion** (e.g., Honeywell turbocharger connecting rod), enhancing efficiency and reducing costs. - **Materials:** High-performance polymers like **PEEK, Torlon, LCP, PPS**. - **Clients:** GE Appliances, Haier, Garrett, Schaeffler. #### Strategic Advantages: - One of **India’s few licensed processors of Torlon**. - Expertise in structural and functional plastic substitution with identical lifecycle performance. - Participation in global megatrends: **electrification, fuel efficiency, smart appliances**. --- ### **Global Expansion & Innovation Infrastructure** #### **UK Subsidiary – Shaily Innovations Limited** - Acts as the **global innovation hub** for medical device development. - Focus: End-to-end design, prototyping, DFM, regulatory compliance, **human factors engineering**. - Participates in key events: **Pharma Pack, CPHI, PDA, PODD**. #### **Dubai Subsidiary – Shaily Innovations FZCO (Jan 2025)** - Wholly-owned and led by Amit Sanghvi. - Focused on expanding **market access in Middle East and Asia-Pacific**. - Offers design and development services for **pen-type delivery systems**. - Part of a long-term plan to establish **multi-geography manufacturing**. #### **R&D & Capabilities** - 15-member R&D team (expanding). - Specialized focus: **vendor development, packaging, advanced molding** (sandwich, foam, insert). - Innovation pipeline includes **soft mist inhalers, on-body injectors, high-viscosity auto-injectors**. - CT scanner, CMM, advanced metrology for **micron-level defect detection**. --- ### **Operational Excellence** - **Certifications:** ISO 9001, IATF 16949, ISO 13485, MDSAP, SCAN, AEO. - **Automation:** Robotics integrated across molding and assembly lines for consistent quality and reduced cycle time. - **Digitalization:** ERP, MES, IoT for predictive maintenance and real-time monitoring. - **Lean Manufacturing:** Kaizen, Six Sigma, and continuous improvement culture. - **Backward Integration:** State-of-the-art **tool room** with CNC machines from GF, Yasda, Makino, Zeiss—enabling faster prototyping and mold quality control. --- ### **Financial & Capital Strategy** - **Revenue (FY25):** ₹644 crores (FY24: ₹607 crores; FY23: ~₹584 crores). - **EBITDA Growth (FY25):** 44.52%, reflecting **high operating leverage** post-capex. - **Net Profit (FY24):** ₹57 crores (+63% YoY). - **Market Valuation:** ₹8,397.6 crores as of FY25 (₹943 cr in FY23), **book value ₹119.18/share**. - **Debt:** **Zero long-term debt** — funded entirely through internal accruals. - **Capex (Last 5 Years):** ₹482.74 crore, with ₹150 crore focused on healthcare in FY25–26 alone. > *“Our de-risked, scalable model and strong cash flow allow us to invest in high-return initiatives without financial constraints.”* --- ### **Sustainability & ESG** - Use of **recyclable polymers** and **bioplastics**. - **Energy-efficient processes** (LED lighting, automated UV coatings). - Harmonic arresters reduce power fluctuations and maintenance. - Compliance with international **EHS and chemical standards**. ---